Peringatan Keamanan

Patients experiencing an overdose may present with local anesthetic systemic toxicity syndrome, decreased cardiovascular function, decreased central nervous system function, cardiac arrest, bradycardia, hypotension, cardiac arrhythmias, syncope, and seizures.A231219 Patients should be treated with symptomatic and supportive measures which include airway maintenance, controlling seizures, and hemodynamic stabilization.A231219

Benzocaine

DB01086

small molecule approved investigational

Deskripsi

Benzocaine is an ester local anesthetic that acts by preventing transmission of impulses along nerve fibers and at nerve endings.A231219 It is commonly used for local anesthesia in many over the counter products.L32454,L32459,L32464 Benzocaine was first used for local anesthesia in dentistry.A231259

Struktur Molekul 2D

Berat 165.1891
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Benzocaine undergoes ester hydrolysis to form 4-aminobenzoic acid, acetylation to form acetylbenzocaine, or N-hydroxylation to form benzocaine hydroxide.A231094 4-aminobenzoic acid can be acetylated or acetylbenzocaine can undergo ester hydrolysis to form 4-acetaminobenzoic acid.A231094

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1951 Data
Deferasirox The serum concentration of Benzocaine can be increased when it is combined with Deferasirox.
Peginterferon alfa-2b The serum concentration of Benzocaine can be increased when it is combined with Peginterferon alfa-2b.
Leflunomide The serum concentration of Benzocaine can be decreased when it is combined with Leflunomide.
Teriflunomide The serum concentration of Benzocaine can be decreased when it is combined with Teriflunomide.
Buprenorphine Benzocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.
Hydrocodone Benzocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.
Magnesium sulfate The therapeutic efficacy of Benzocaine can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Benzocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Benzocaine may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.
Mirtazapine Benzocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.
Orphenadrine Benzocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Benzocaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.
Pramipexole Benzocaine may increase the sedative activities of Pramipexole.
Ropinirole Benzocaine may increase the sedative activities of Ropinirole.
Rotigotine Benzocaine may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Benzocaine.
Sodium oxybate Benzocaine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Benzocaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.
Thalidomide Benzocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Benzocaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Dabrafenib The serum concentration of Benzocaine can be decreased when it is combined with Dabrafenib.
Luliconazole The serum concentration of Benzocaine can be increased when it is combined with Luliconazole.
Prilocaine The risk or severity of methemoglobinemia can be increased when Benzocaine is combined with Prilocaine.
Hyaluronidase (ovine) Hyaluronidase (ovine) can cause an increase in the absorption of Benzocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Hyaluronidase (human recombinant) Hyaluronidase (human recombinant) can cause an increase in the absorption of Benzocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Hyaluronidase Hyaluronidase can cause an increase in the absorption of Benzocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Benzocaine.
Mirabegron The serum concentration of Benzocaine can be increased when it is combined with Mirabegron.
Abiraterone The serum concentration of Benzocaine can be increased when it is combined with Abiraterone.
Cyproterone acetate The metabolism of Benzocaine can be increased when combined with Cyproterone acetate.
Azelastine Benzocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.
Citalopram The risk or severity of adverse effects can be increased when Benzocaine is combined with Citalopram.
Trazodone The risk or severity of adverse effects can be increased when Benzocaine is combined with Trazodone.
Sertraline The risk or severity of adverse effects can be increased when Benzocaine is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Benzocaine is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Benzocaine is combined with Nefazodone.
Zimelidine The risk or severity of adverse effects can be increased when Benzocaine is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Benzocaine is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Benzocaine is combined with Milnacipran.
Desvenlafaxine The serum concentration of Benzocaine can be increased when it is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Benzocaine is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Benzocaine is combined with Indalpine.
Alaproclate The risk or severity of adverse effects can be increased when Benzocaine is combined with Alaproclate.
Lumacaftor The serum concentration of Benzocaine can be decreased when it is combined with Lumacaftor.
Dapsone The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Benzocaine.
Technetium Tc-99m tilmanocept Benzocaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.
Trospium The metabolism of Benzocaine can be decreased when combined with Trospium.
Benzatropine The metabolism of Benzocaine can be decreased when combined with Benzatropine.
Disopyramide The metabolism of Benzocaine can be decreased when combined with Disopyramide.
Olanzapine The risk or severity of CNS depression can be increased when Olanzapine is combined with Benzocaine.
Promazine The risk or severity of CNS depression can be increased when Promazine is combined with Benzocaine.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Benzocaine.
Gallamine triethiodide The risk or severity of CNS depression can be increased when Gallamine triethiodide is combined with Benzocaine.
Triflupromazine The risk or severity of CNS depression can be increased when Triflupromazine is combined with Benzocaine.
Lamotrigine The risk or severity of methemoglobinemia can be increased when Lamotrigine is combined with Benzocaine.
Rocuronium The risk or severity of CNS depression can be increased when Rocuronium is combined with Benzocaine.
Scopolamine The risk or severity of CNS depression can be increased when Scopolamine is combined with Benzocaine.
Clidinium The risk or severity of CNS depression can be increased when Clidinium is combined with Benzocaine.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Benzocaine.
Biperiden The metabolism of Benzocaine can be decreased when combined with Biperiden.
Brompheniramine The risk or severity of CNS depression can be increased when Brompheniramine is combined with Benzocaine.
Flupentixol The risk or severity of CNS depression can be increased when Flupentixol is combined with Benzocaine.
Cocaine The risk or severity of methemoglobinemia can be increased when Cocaine is combined with Benzocaine.
Maprotiline The risk or severity of CNS depression can be increased when Maprotiline is combined with Benzocaine.
Tolterodine The metabolism of Benzocaine can be decreased when combined with Tolterodine.
Oxybutynin The metabolism of Benzocaine can be decreased when combined with Oxybutynin.
Promethazine The risk or severity of CNS depression can be increased when Promethazine is combined with Benzocaine.
Diphenhydramine The risk or severity of methemoglobinemia can be increased when Diphenhydramine is combined with Benzocaine.
Doxacurium The risk or severity of CNS depression can be increased when Benzocaine is combined with Doxacurium.
Doxepin The risk or severity of CNS depression can be increased when Benzocaine is combined with Doxepin.
Quetiapine The risk or severity of CNS depression can be increased when Benzocaine is combined with Quetiapine.
Mivacurium The risk or severity of CNS depression can be increased when Benzocaine is combined with Mivacurium.
Aripiprazole The risk or severity of CNS depression can be increased when Benzocaine is combined with Aripiprazole.
Chlorprothixene The risk or severity of CNS depression can be increased when Benzocaine is combined with Chlorprothixene.
Metocurine The risk or severity of CNS depression can be increased when Benzocaine is combined with Metocurine.
Pancuronium The risk or severity of CNS depression can be increased when Benzocaine is combined with Pancuronium.
Pipecuronium The risk or severity of CNS depression can be increased when Benzocaine is combined with Pipecuronium.
Tiotropium The metabolism of Tiotropium can be decreased when combined with Benzocaine.
Solifenacin The metabolism of Solifenacin can be decreased when combined with Benzocaine.
Rapacuronium The risk or severity of CNS depression can be increased when Benzocaine is combined with Rapacuronium.
Pizotifen The risk or severity of CNS depression can be increased when Benzocaine is combined with Pizotifen.
Fesoterodine The metabolism of Fesoterodine can be decreased when combined with Benzocaine.
Benactyzine The risk or severity of CNS depression can be increased when Benzocaine is combined with Benactyzine.
Umeclidinium The metabolism of Umeclidinium can be decreased when combined with Benzocaine.
Revefenacin The metabolism of Revefenacin can be decreased when combined with Benzocaine.
Emepronium The risk or severity of CNS depression can be increased when Benzocaine is combined with Emepronium.
Carbamazepine The risk or severity of methemoglobinemia can be increased when Carbamazepine is combined with Benzocaine.
Primidone The risk or severity of methemoglobinemia can be increased when Primidone is combined with Benzocaine.
Albendazole The metabolism of Benzocaine can be increased when combined with Albendazole.
Rifampin The risk or severity of methemoglobinemia can be increased when Rifampicin is combined with Benzocaine.
Caffeine The metabolism of Benzocaine can be decreased when combined with Caffeine.

Target Protein

Sodium channel protein type 10 subunit alpha SCN10A

Referensi & Sumber

Artikel (PubMed)
  • PMID: 25010377
    Hartman NR, Mao JJ, Zhou H, Boyne MT 2nd, Wasserman AM, Taylor K, Racoosin JA, Patel V, Colatsky T: More methemoglobin is produced by benzocaine treatment than lidocaine treatment in human in vitro systems. Regul Toxicol Pharmacol. 2014 Oct;70(1):182-8. doi: 10.1016/j.yrtph.2014.07.002. Epub 2014 Jul 8.
  • PMID: 17175824
    Becker DE, Reed KL: Essentials of local anesthetic pharmacology. Anesth Prog. 2006 Fall;53(3):98-108; quiz 109-10. doi: 10.2344/0003-3006(2006)5398:EOLAP2.0.CO;2.
  • PMID: 19661462
    Hanck DA, Nikitina E, McNulty MM, Fozzard HA, Lipkind GM, Sheets MF: Using lidocaine and benzocaine to link sodium channel molecular conformations to state-dependent antiarrhythmic drug affinity. Circ Res. 2009 Aug 28;105(5):492-9. doi: 10.1161/CIRCRESAHA.109.198572. Epub 2009 Aug 6.
  • PMID: 31082097
    Singh R, Al Khalili Y: Benzocaine .
  • PMID: 15197044
    Moore TJ, Walsh CS, Cohen MR: Reported adverse event cases of methemoglobinemia associated with benzocaine products. Arch Intern Med. 2004 Jun 14;164(11):1192-6. doi: 10.1001/archinte.164.11.1192.
  • PMID: 26061572
    de Freiras GC, Pozzobon RT, Blaya DS, Moreira CH: Efficacy of Benzocaine 20% Topical Anesthetic Compared to Placebo Prior to Administration of Local Anesthesia in the Oral Cavity: A Randomized Controlled Trial. Anesth Prog. 2015 Summer;62(2):46-50. doi: 10.2344/0003-3006-62.2.46.
  • PMID: 17377783
    Kitamura K, Omran AA, Takegami S, Tanaka R, Kitade T: (19)F NMR spectroscopic characterization of the interaction of niflumic acid with human serum albumin. Anal Bioanal Chem. 2007 Apr;387(8):2843-8. doi: 10.1007/s00216-007-1162-x. Epub 2007 Feb 14.
  • PMID: 27754990
    Hieger MA, Afeld JL, Cumpston KL, Wills BK: Topical Benzocaine and Methemoglobinemia. Am J Ther. 2017 Sep/Oct;24(5):e596-e598. doi: 10.1097/MJT.0000000000000521.
Menampilkan 8 dari 10 artikel.

Contoh Produk & Brand

Produk: 1532 • International brands: 4
Produk
  • 10 Person ANSI
    Kit • - • Ophthalmic; Oral; Topical • US • OTC
  • 20/20 Topical Anesthetic
    Strip • 10 mg/1 • Dental • US • OTC
  • 25 Person ANSI
    Kit • - • Ophthalmic; Oral; Topical • US • OTC
  • 2x Med Liq
    Liquid • - • Oral • US • OTC
  • 2x Med Liq
    Liquid • - • Oral • US • OTC
  • 3M Nexcare Cold Sore Treatment
    Ointment • - • Topical • US • OTC
  • 3x Medicated Mouth Sore Gel
    Gel • - • Oral • US • OTC
  • 3x Medicated Mouth Sore Gel
    Gel • - • Oral • US • OTC
Menampilkan 8 dari 1532 produk.
International Brands
  • Anacaine
  • Anaesthesin
  • Anbesol Baby
  • Dermoplast

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul